Keyword: Giovanni Caforio
The FDA cited manufacturing problems in refusing to review Bristol Myers' submission for a CAR-T cell therapy developed with bluebird.
BMS CEO Giovanni Caforio's pay dipped slightly to $18.8 million last year, as his incentives were tied to the successful integration of Celgene.
Barclays M&A veteran Elizabeth Mily will take over as business development chief as BMS looks for long-term growth beyond Opdivo.
Bristol Myers Squibb unveiled its new corporate identity this week. Gone is the old blue logo, geometric glyph and hyphenated name.
Sales of Bristol Myers-Squibb’s cancer blockbuster Opdivo fell 2% in the fourth quarter, products picked up from Celgene picked up the slack.
With BMS' Celgene deal recently closed, CEO Giovanni Caforio says he feels “even better about our opportunity” then he did when Bristol unveiled it.
Bristol CEO Caforio figures the company's Celgene buy will fortify its position regardless of where the ongoing drug pricing debate goes.
Bristol-Myers is counting on new talent from Novartis and Celgene—and a revamped R&D chart—to buck up its existing drugs and new launches.
Bristol-Myers Squibb plans to take on tens of billions in new debt to fund its Celgene buy, but execs have said they plan to quickly pay it down.